Citadel Advisors - AN2 THERAPEUTICS INC ownership

AN2 THERAPEUTICS INC's ticker is and the CUSIP is 037326105. A total of 19 filers reported holding AN2 THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
Citadel Advisors ownership history of AN2 THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$25,029,356
+120.2%
1,556,552
+16.4%
0.01%
+150.0%
Q2 2023$11,364,356
-13.9%
1,336,983
-0.0%
0.00%
-33.3%
Q1 2023$13,197,759
+3.6%
1,337,159
+0.0%
0.00%0.0%
Q4 2022$12,741,448
-45.2%
1,336,9830.0%0.00%
-40.0%
Q3 2022$23,237,000
+134.1%
1,336,983
+0.2%
0.01%
+66.7%
Q2 2022$9,924,000
-51.8%
1,333,816
-6.1%
0.00%
-25.0%
Q1 2022$20,593,0001,419,8510.00%
Other shareholders
AN2 THERAPEUTICS INC shareholders Q1 2022
NameSharesValueWeighting ↓
Monashee Investment Management LLC 433,330$6,530,0001.89%
RA Capital Management 3,666,663$55,257,0001.21%
BVF INC/IL 1,616,665$24,363,0000.98%
Avidity Partners Management LP 688,330$10,373,0000.22%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 584,136$8,803,0000.20%
COWEN AND COMPANY, LLC 60,278$908,0000.09%
Woodline Partners LP 150,000$2,261,0000.04%
Alyeska Investment Group, L.P. 125,000$1,884,0000.02%
Citadel Advisors 1,419,851$20,593,0000.00%
Anson Funds Management LP 2,500$38,0000.00%
View complete list of AN2 THERAPEUTICS INC shareholders